You Don't Need to Pay List Price
The list prices for GLP-1 medications are alarming: $1,349/month for Wegovy, $1,060/month for Zepbound, $969/month for Ozempic. But almost nobody should be paying those numbers in 2026.
Between manufacturer programs, compounded options, insurance strategies, tax benefits, and the upcoming Medicare bridge, there are more ways to reduce GLP-1 costs than ever before. This guide covers every single one.
The Range
Real patients are paying anywhere from $25 to $349/mo in 2026. Your actual cost depends on which strategies you stack.
Strategy 1: Manufacturer Savings Programs
Novo Nordisk (Wegovy / Ozempic)
Wegovy Pill Intro — $149/mo: Self-pay price through NovoCare Pharmacy for the 1.5mg and 4mg daily tablets. No insurance needed. The 4mg offer is available through April 15, 2026 (then goes to $199/mo).
Wegovy/Ozempic Injection Intro — $199/mo: New patients starting on 0.25mg or 0.5mg doses pay $199/month for the first two fills via NovoCare. Available through June 30, 2026.
Wegovy Savings Card — As Low as $25/mo: For commercially insured patients with coverage. The card covers up to $100/month in copay costs for up to 48 months. Government beneficiaries excluded. This is the cheapest possible path for insured patients.
Eli Lilly (Zepbound / Mounjaro)
Zepbound Vials — From $299/mo: Eli Lilly's direct self-pay program through LillyDirect. Single-dose vials available at all dose levels. This is the cheapest brand-name tirzepatide access.
Zepbound KwikPen Self-Pay — $449/mo: For 7.5–15mg maintenance doses. The convenient KwikPen format at a flat monthly rate. Available through December 31, 2026.
Strategy 2: Compounded GLP-1 Medications
Compounded GLP-1 medications are custom-prepared by licensed compounding pharmacies. They are not FDA-approved and have not been evaluated for safety, effectiveness, or quality. However, they remain the lowest-cost access point for many patients.
Compounded semaglutide ranges from about $146–$299/month, and compounded tirzepatide from about $258–$400/month, depending on the provider and dose.
| Provider | Semaglutide From | Tirzepatide From | Key Feature |
|---|---|---|---|
| Yucca Health | $146/mo | $258/mo | Lowest intro price |
| MEDVi | $179/mo | $279/mo | No membership fee, oral options |
| SHED | $199/mo | Available | Weight-loss guarantee, drops/lozenges |
| Synergy Rx | $200/mo | — | All-inclusive, no hidden fees |
SHED — From $199/mo
Compounded semaglutide and tirzepatide with a 10% weight-loss guarantee. Choose injectable, drops, or lozenges. FSA/HSA accepted.
Check Availability →Sponsored · Compounded medications are not FDA-approved.
Strategy 3: Insurance Optimization
Step therapy approach: Many insurers require you to "fail" cheaper weight loss interventions before approving GLP-1 coverage. Ask your doctor to document previous diet, exercise, and medication attempts in your chart. This creates a paper trail for the prior authorization.
Diabetes vs. weight loss: If you have a type 2 diabetes or pre-diabetes diagnosis, coverage for Ozempic or Mounjaro (the diabetes-labeled versions of semaglutide and tirzepatide) is significantly better than coverage for Wegovy or Zepbound. Ask your provider about this pathway.
Denial appeals: About 40–50% of initial GLP-1 prior authorizations are denied. But a significant percentage of appeals succeed. Your provider can submit a letter of medical necessity citing your BMI, comorbidities, and failed alternatives. Don't accept the first denial as final.
Strategy 4: HSA and FSA Tax Benefits
GLP-1 medications prescribed for a medical condition are generally eligible for HSA (Health Savings Account) and FSA (Flexible Spending Account) reimbursement. Both compounded and brand-name prescriptions typically qualify.
Paying with pre-tax HSA/FSA dollars effectively saves you 22–37% depending on your marginal tax bracket. On a $200/month medication, that's $44–$74/month in tax savings — real money over a year.
Strategy 5: Medicare Coverage (Starting July 2026)
The Treat and Reduce Obesity Act provision in recent legislation directs Medicare Part D plans to cover anti-obesity medications beginning July 1, 2026. A temporary bridge program will cap copays at $50/month through December 31, 2026.
This is the first time Medicare has ever covered weight loss medications. If you're on Medicare and currently paying out of pocket for GLP-1s, July 2026 will cut your costs dramatically.
Strategy 6: Patient Assistance Programs
For low-income, uninsured patients, both Novo Nordisk and Eli Lilly offer patient assistance programs that provide medication for free. Eligibility is typically based on household income at or below 400% of the federal poverty level.
These programs are underutilized — many patients don't know they exist. Ask your prescribing provider or check the manufacturers' websites directly.
Stacking Strategies: Maximum Savings
The most cost-effective approach combines multiple strategies:
Best case (insured): Wegovy with insurance + savings card + HSA = as low as $0–$25/month after tax benefits.
Best case (uninsured): Wegovy pill $149/mo intro + HSA = approximately $95–$115/month effective cost.
Best case (Medicare): Medicare bridge at $50/mo starting July 2026 — the simplest path.
Synergy Rx — From $200/mo
All-inclusive compounded semaglutide. No hidden fees — consultation, medication, and shipping bundled into one price.
Check Availability →Sponsored · Compounded medications are not FDA-approved.
The Bottom Line
Nobody should pay $1,000+/month for GLP-1 medication in 2026. With the strategies above, realistic monthly costs range from $25 (insured with savings card) to $349 (brand-name self-pay maintenance). Most patients will land somewhere between $149 and $250/month.
Use our True Monthly Cost Calculator to model your specific scenario, or compare all provider prices side by side.